RESULTS
CORONAVIRUS DISEASE 2019
Between January 2019 and March 2021, 115 children from Uganda, Zambia, and Zimbabwe randomized to receive a TAF regimen were included in the pharmacokinetic substudy and contributed 116 pharmacokinetic curves. Of the 116 pharmacokinetic curves, 104 curves in 104 children were evaluable and included in the NCA (Participant flowchart of children included in the pharmacokinetic substudy. *Two exclusions from the same participant. Abbreviations: COVID-19, Coronavirus Disease 2019; PK, pharmacokinetic; TAF, tenofovir alafenamide fumarate.All pharmacokinetic data of TAF and TFV are reported in Demographics of Participants and Pharmacokinetic Parameters of Tenofovir Alafenamide Fumarate and Tenofovir in Combination With 1 of 4 Anchor DrugsPharmacokinetic data (except TAbbreviations: ATV/r, atazanavir/ritonavir; AUC, area under the concentration–time curve from 0 to 24 h (AUCBased on 33 participants because the AUCGM (CV%) TAF CThe TFV GM (CV%) AUCTFV CPharmacokinetic parameters of TAF and TFV by anchor drug combinations are shown in Median tenofovir alafenamide fumarate (TAF) plasma concentration (upper) and mean tenofovir (TFV) plasma concentration (lower) versus time curves of children on TAF combined with dolutegravir (DTG), atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or lopinavir/ritonavir (LPV/r). Twenty-two of 104 (21%) children did not have a sample at 0.5 h after dose: 6 on DTG, 6 on ATV/r, 5 on DRV/r, and 5 on LPV/r.Area under the concentration–time curve (AUC) from 0 to the last sample with a measurable concentration (AUC